Brachytherapy Application with in Situ Dose Painting Administered by Gold Nanoparticle Eluters

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2014 Dec 9

PMID 25482302

Citations 18

Authors

Neeharika Sinha

Gizem Cifter

Erno Sajo

Rajiv Kumar

Srinivas Sridhar

Paul L Nguyen

Robert A Cormack

G Mike Makrigiorgos

Wilfred Ngwa

Affiliations

Soon will be listed here.

Abstract

Purpose: Recent studies show promise that administering gold nanoparticles (GNP) to tumor cells during brachytherapy could significantly enhance radiation damage to the tumor. A new strategy proposed for sustained administration of the GNP in prostate tumors is to load them into routinely used brachytherapy spacers for customizable in situ release after implantation. This in silico study investigated the intratumor biodistribution and corresponding dose enhancement over time due to GNP released from such GNP-loaded brachytherapy spacers (GBS).

Method And Materials: An experimentally determined intratumoral diffusion coefficient (D) for 10-nm nanoparticles was used to estimate D for other sizes by using the Stokes-Einstein equation. GNP concentration profiles, obtained using D, were then used to calculate the corresponding dose enhancement factor (DEF) for each tumor voxel, using dose painting-by-numbers approach, for times relevant to the considered brachytherapy sources' lifetimes. The investigation was carried out as a function of GNP size for the clinically applicable low-dose-rate brachytherapy sources iodine-125 (I-125), palladium-103 (Pd-103), and cesium-131 (Cs-131).

Results: Results showed that dose enhancement to tumor voxels and subvolumes during brachytherapy can be customized by varying the size of GNP released or eluted from the GBS. For example, using a concentration of 7 mg/g GNP, significant DEF (>20%) could be achieved 5 mm from a GBS after 5, 12, 25, 46, 72, 120, and 195 days, respectively, for GNP sizes of 2, 5, 10, 20, 30, and 50 nm and for 80 nm when treating with I-125.

Conclusions: Analyses showed that using Cs-131 provides the highest dose enhancement to tumor voxels. However, given its relatively longer half-life, I-125 presents the most flexibility for customizing the dose enhancement as a function of GNP size. These findings provide a useful reference for further work toward development of potential new brachytherapy application with in situ dose painting administered via gold nanoparticle eluters for prostate cancer.

Citing Articles

The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment.

Haque M, Shakil M, Mahmud K Cancers (Basel). 2023; 15(6).

PMID: 36980778 PMC: 10047050. DOI: 10.3390/cancers15061892.

Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.

Goel M, Mackeyev Y, Krishnan S Cancer Nanotechnol. 2023; 14(1):15.

PMID: 36865684 PMC: 9968708. DOI: 10.1186/s12645-023-00165-y.

Image-Based Quantification of Gold Nanoparticle Uptake and Localization in 3D Tumor Models to Inform Radiosensitization Schedule.

Petrovic L, Oumano M, Hanlon J, Arnoldussen M, Koruga I, Yasmin-Karim S Pharmaceutics. 2022; 14(3).

PMID: 35336040 PMC: 8953383. DOI: 10.3390/pharmaceutics14030667.

Imaging and Characterization of Sustained Gadolinium Nanoparticle Release from Next Generation Radiotherapy Biomaterial.

Mueller R, Moreau M, Yasmin-Karim S, Protti A, Tillement O, Berbeco R Nanomaterials (Basel). 2020; 10(11).

PMID: 33202903 PMC: 7697013. DOI: 10.3390/nano10112249.

Delivery of Nanoparticle-Based Radiosensitizers for Radiotherapy Applications.

Boateng F, Ngwa W Int J Mol Sci. 2020; 21(1).

PMID: 31906108 PMC: 6981554. DOI: 10.3390/ijms21010273.

References

Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde R, Sastry M . Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir. 2005; 21(23):10644-54. DOI: 10.1021/la0513712. View

Hainfeld J, Slatkin D, Smilowitz H . The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004; 49(18):N309-15. DOI: 10.1088/0031-9155/49/18/n03. View

Jain R . Taming vessels to treat cancer. Sci Am. 2008; 298(1):56-63. DOI: 10.1038/scientificamerican0108-56. View

Bennewith K, Dedhar S . Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer. 2011; 11:504. PMC: 3247198. DOI: 10.1186/1471-2407-11-504. View

Jain S, Hirst D, OSullivan J . Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2011; 85(1010):101-13. PMC: 3473940. DOI: 10.1259/bjr/59448833. View

Lasagna-Reeves C, Gonzalez-Romero D, Barria M, Olmedo I, Clos A, Ramanujam V . Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun. 2010; 393(4):649-55. DOI: 10.1016/j.bbrc.2010.02.046. View

Arvizo R, Bhattacharya R, Mukherjee P . Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv. 2010; 7(6):753-63. PMC: 2874072. DOI: 10.1517/17425241003777010. View

Makadia H, Siegel S . Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2012; 3(3):1377-1397. PMC: 3347861. DOI: 10.3390/polym3031377. View

Jain R . Delivery of molecular and cellular medicine to solid tumors. J Control Release. 1998; 53(1-3):49-67. DOI: 10.1016/s0168-3659(97)00237-x. View

10.

Connor E, Mwamuka J, Gole A, Murphy C, Wyatt M . Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2006; 1(3):325-7. DOI: 10.1002/smll.200400093. View

11.

Cole A . Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res. 1969; 38(1):7-33. View

12.

Zygmanski P, Liu B, Tsiamas P, Cifter F, Petersheim M, Hesser J . Dependence of Monte Carlo microdosimetric computations on the simulation geometry of gold nanoparticles. Phys Med Biol. 2013; 58(22):7961-77. DOI: 10.1088/0031-9155/58/22/7961. View

13.

Hainfeld J, Slatkin D, Focella T, Smilowitz H . Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006; 79(939):248-53. DOI: 10.1259/bjr/13169882. View

14.

Jain R, Stylianopoulos T . Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7(11):653-64. PMC: 3065247. DOI: 10.1038/nrclinonc.2010.139. View

15.

Kuban D, Levy L, Cheung M, Lee A, Choi S, Frank S . Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys. 2010; 79(5):1310-7. DOI: 10.1016/j.ijrobp.2010.01.006. View

16.

Eichelberger L, Koch M, Eble J, Ulbright T, Juliar B, Cheng L . Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol. 2005; 18(7):886-90. DOI: 10.1038/modpathol.3800405. View

17.

Nagesha D, Tada D, Stambaugh C, Gultepe E, Jost E, Levy C . Radiosensitizer-eluting nanocoatings on gold fiducials for biological in-situ image-guided radio therapy (BIS-IGRT). Phys Med Biol. 2010; 55(20):6039-52. DOI: 10.1088/0031-9155/55/20/001. View

18.

Cho S, Jones B, Krishnan S . The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol. 2009; 54(16):4889-905. PMC: 3064075. DOI: 10.1088/0031-9155/54/16/004. View

19.

Montenegro M, Nahar S, Pradhan A, Huang K, Yu Y . Monte Carlo simulations and atomic calculations for Auger processes in biomedical nanotheranostics. J Phys Chem A. 2009; 113(45):12364-9. DOI: 10.1021/jp905323y. View

20.

Pradhan A, Nahar S, Montenegro M, Yu Y, Zhang H, Sur C . Resonant X-ray enhancement of the Auger effect in high-Z atoms, molecules, and nanoparticles: potential biomedical applications. J Phys Chem A. 2009; 113(45):12356-63. DOI: 10.1021/jp904977z. View